DNA
NYSE
US
Ginkgo Bioworks Holdings, Inc. Class A Common Stock
$7.98
▲ +$0.03
(+0.31%)
Vol 259K
Mkt Cap
$487.8M
ROE
-53.7%
Margin
-183.8%
Beta
1.68
52W
$5–$18
Wall Street Consensus
11 analysts · Apr 20260
Strong Buy
1
Buy
2
Hold
5
Sell
3
Strong Sell
9.1%
Buy Rating
Price Chart
Similar Stocks
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
PSNL
Personalis Inc
$706.9M
CTKB
Cytek Biosciences Inc
$645.7M
MLAB
Mesa Laboratories Inc
$433.5M
CYRX
Cryoport Inc
P/E 7.1
$480.7M
PACB
Pacific Biosciences of California Inc
$564.6M
NAUT
Nautilus Biotechnology Inc
$246.3M
LAB
Standard BioTools Inc
$492.2M
CDXS
Codexis Inc
$147.2M
QSI
Quantum-Si Inc
$237.0M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.47 | $-1.41 | +$0.06 |
| Sep 2025 | $-1.25 | $-1.45 | $-0.20 |
| Jun 2025 | $-1.58 | $-1.10 | +$0.48 |
| Mar 2025 | $-1.79 | $-1.68 | +$0.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $43.8M | $48.3M | $49.6M | $38.8M | $33.4M |
| Net Income | — | -$107.5M | -$91.0M | -$60.3M | -$80.8M | -$80.8M |
Fundamentals Trend
| Metric | 2026-04-12 | 2026-04-17 |
|---|---|---|
| ROE (TTM) | -53.7% | -53.7% |
| P/E (TTM) | — | — |
| Net Margin | -183.8% | -183.8% |
| Gross Margin | 72.4% | 72.4% |
| D/E Ratio | — | — |
| Current Ratio | 4.92 | 4.92 |
Key Ratios
ROA (TTM)
-25.9%
P/S (TTM)
2.87
P/B
1.0
EPS (TTM)
$-5.64
CF/Share
$-0.41
Rev Growth 3Y
-29.1%
52W High
$17.58
52W Low
$5.37
$5.37
52-Week Range
$17.58
Financial Health
Free Cash Flow
-$47.7M
Net Debt
$272.7M
Cash
$167.2M
Total Debt
$439.9M
As of Dec 31, 2025
How does DNA compare to Life Sciences Tools & Services peers?
Peer group: Peers · Life Sciences Tools & Services (Peers) · 10 companies
DNA valuation vs Life Sciences Tools & Services peers
P/E ratio
—
▼
0%
below
peers
(27.5)
vs Peers
vs Industry
Undervalued
P/S ratio
2.3
▼
39%
below
peers
(3.8)
vs Peers
vs Industry
Undervalued
P/B ratio
1.0
▼
31%
below
peers
(1.4)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.4%)
vs Peers
vs Industry
Low yield
DNA profitability vs Life Sciences Tools & Services peers
ROE
-53.7%
▼
68%
below
peers
(-31.9%)
vs Peers
vs Industry
Weak
Net margin
-183.8%
▼
85%
below
peers
(-99.6%)
vs Peers
vs Industry
Weak
Gross margin
72.4%
▲
63%
above
peers
(44.5%)
vs Peers
vs Industry
Top tier
ROA
-25.9%
▼
13%
below
peers
(-23.0%)
vs Peers
vs Industry
Weak
DNA financial health vs Life Sciences Tools & Services peers
D/E ratio
—
▼
0%
below
peers
(0.2)
vs Peers
vs Industry
High debt
Current ratio
4.9
▼
1%
below
peers
(5.0)
vs Peers
vs Industry
In line
Beta
1.6
▲
31%
above
peers
(1.2)
vs Peers
vs Industry
More volatile
DNA fundamentals radar
DNA
Peer median
Industry
DNA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio